News >

Novel Agents Advance Acute Leukemia Treatment, But Challenges Remain

Caroline Seymour
Published: Tuesday, May 08, 2018

Michael R. Grunwald, MD

Michael R. Grunwald, MD
While tremendous strides have been made in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), challenges remain in both paradigms, including optimal sequencing and managing toxicity profiles, explained Michael R. Grunwald, MD.

on Hematologic Malignancies, Grunwald, a physician at Levine Cancer Institute, discussed new and emerging agents in AML and ALL, as well as sequencing and toxicity challenges with these treatments.

OncLive: Please provide an overview of your presentation.

Grunwald: I presented on new therapies in acute leukemia, specifically AML and ALL. For many decades, we didn't have new therapies, especially for AML. Over the past few years, especially this past year, we've gotten some exciting new drug approvals in both AML and ALL.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication